Chinese Atrial Fibrillation Registry
China-AF
1 other identifier
observational
100,000
1 country
2
Brief Summary
This prospective, observational cohort study aims to establish a long-term registry of adult patients with atrial fibrillation (AF) in China to comprehensively characterize patient profiles and evaluate real-world management and outcomes over time. The objectives of the study are to:
- Describe the demographic, clinical, and treatment characteristics of AF patients across different stages of disease progression.
- Assess the effectiveness and safety of various AF treatment strategies, including oral anticoagulation, catheter ablation, and left atrial appendage closure, in routine clinical practice.
- Identify patient- and treatment-related factors that influence therapeutic outcomes.
- Explore the role of advanced technologies and artificial intelligence in improving procedural performance, risk stratification, and clinical decision-making in AF care. Participants will undergo standardized baseline evaluation and longitudinal follow-up to collect data on heart rhythm monitoring, treatment exposures, healthcare utilization, clinical events, and patient-reported outcomes. This cohort will generate real-world evidence to inform personalized and evidence-based management of AF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2011
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
May 16, 2025
CompletedFirst Posted
Study publicly available on registry
May 23, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2035
May 23, 2025
May 1, 2025
24.4 years
May 16, 2025
May 16, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
All-cause death
Death due to any cause.
10 years
Secondary Outcomes (9)
Ischemic Stroke
5 years
Hemorrhagic Stroke
5 years
Transient ischemic attack (TIA)
5 years
Cardiovascular Death
5 years
Cardiovascular Hospitalization
5 years
- +4 more secondary outcomes
Eligibility Criteria
Adults (≥18 years) with documented atrial fibrillation enrolled from multiple hospitals across China.
You may qualify if:
- Age ≥ 18 years;
- Documented atrial fibrillation episode lasting \>30 seconds confirmed by electrocardiogram (ECG), Holter monitor, implantable cardiac monitor, or wearable ECG device
- Signed informed consent and willingness to participate in follow-up
You may not qualify if:
- Atrial fibrillation due to a reversible cause (e.g., transient secondary AF)
- Presence of comorbid conditions associated with an expected life expectancy of less than 1 year
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100029, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Changsheng Ma, MD
Beijing Anzhen Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 16, 2025
First Posted
May 23, 2025
Study Start
August 1, 2011
Primary Completion (Estimated)
December 31, 2035
Study Completion (Estimated)
December 31, 2035
Last Updated
May 23, 2025
Record last verified: 2025-05